Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension

Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension

Publication date: May 13, 2019

This study provides an opportunity for subjects in the REFALS (3119002; NCT03505021) study to continue treatment with oral levosimendan. The study will also provide more information about long-term safety and effectiveness of oral levosimendan in patients with ALS. This is an open-label study, so that all eligible subjects that complete the double-blind REFALS study (48-weeks of treatment) will have the opportunity to receive oral levosimendan treatment. The primary objective, in addition to continuing treatment for subjects enrolled in the REFALS study, is to evaluate long-term safety of oral levosimendan in ALS patients. Another important objective is to explore long-term effectiveness of oral levosimendan in the treatment of patients with ALS. This study is open only to patients taking part in the REFALS study.

Concepts Keywords
ALS Concurrent illness
Arrhythmia ALS
Atrioventricular Hysterectomy
AV Block Dialysis
Blood Pressure Contraception
Bpm Organ systems
Capsules Medical specialties
Cardiovascular Branches of biology
Concurrent Hepatotoxins
Contraception RTT
Dialysis Lactams
Double Blind Levosimendan
Gastrointestinal Nitriles
Heart Failure Pyridazines
Heart Rate Orion Oyj
Hepatic Heart rate
Hepatic Impairment AV
Hormonal Contraceptive Dialysis
Hysterectomy
Informed Consent
Intrauterine Devices
Menstrual Cycle
Mol
Myocardial Infarction
Neurological
Neuron
Ovulation
Postmenopausal
Pregnancy Test
Progestin
Protocol
Psychiatric Disorder
Recording
Renal
Stroke
Swallow

Semantics

Type Source Name
drug DRUGBANK Levosimendan
disease DOID ALS
gene UNIPROT IGFALS
gene UNIPROT SOD1
disease MESH Development
disease MESH cardiovascular disease
disease MESH myocardial infarction
disease DOID myocardial infarction
disease MESH heart failure
disease MESH arrhythmia
disease MESH stroke
disease DOID stroke
gene UNIPROT REST
gene UNIPROT SHBG
gene UNIPROT CCHCR1
gene UNIPROT DUOXA1
disease MESH renal
gene UNIPROT NR4A2
gene UNIPROT ALG3
disease MESH Motor Neuron Disease
disease DOID Motor Neuron Disease

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *